| 高雄醫學大學 |
2007 |
Transforming Growth Factor-Beta 1 Gene Polymorphisms In High Dose IFN/Ribavirin treated CHC Patients
|
戴嘉言;余明隆;張文宇;李立柏;潘文正;侯乃仁;謝明彥;黃志富;陳信成;林子堯;謝明裕;王良彥;莊萬龍 |
| 高雄醫學大學 |
2007 |
Early Mortality And Responses In Non-Cirrhotic Decompensated CHB Patients With Lamivudine Therapy
|
戴嘉言;余明隆;侯乃仁;謝明彥;李立柏;黃志富;陳信成;王良彥;張文宇;莊萬龍 |
| 高雄醫學大學 |
2007 |
EARLY MORTALITY AND RESPONSES IN NON-CIRRHOTIC PATIENTS WITH CHRONIC HEPATITIS B-RELATED DECOMPENSATION WITH LAMIVUDINE THERAPY: EVALUATION OF MELD AND INDEX SCORING SYSTEMS AS PROGNOSTIC PREDICTORS
|
戴嘉言;余明隆;侯乃仁;謝明彥;李立柏;黃志富;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍 |
| 高雄醫學大學 |
2007 |
The presence of Antinuclear Antibody is associated with a negative response to combination therapy with peginterferon and ribavirin for patients without genotype 1 chronic hepatitis C infection
|
謝明彥;戴嘉言;黃志富;莊萬龍;侯乃仁;李立柏;陳信成;謝明裕;王良彥;張文宇;余明隆 |
| 高雄醫學大學 |
2007 |
High chance of cure in HCV genotype 1 patients with a low viral load achieving an RVR treated for 24 wks with pegylated interferon alfa-2a (PEGASYS) plus ribavirin (COPEGUS): Prospective, randomized, controlled study comparing 24 & 48 wks of treatm
|
余明隆;戴嘉言;黃志富;李立柏;謝明彥;丘長富;侯乃仁;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍* |
| 高雄醫學大學 |
2007 |
PHARMACOGENOMICS STUDY FOR 24 VS. 48 WEEKS TREATMENT OF PEGINTERFERON PLUS RIBAVIRIN FOR GENOTYPE 1b CHRONIC HEPATITIS C
|
戴嘉言;黃志富;謝明彥;陳信成;余明隆;莊萬龍 |
| 高雄醫學大學 |
2007 |
RELATIONSHIP BETWEEN GLUCOSE ABNORMALITIES AND RESPONSE TO PEGYLATED INTERFERON ALFA PLUS RIBAVIRIN COMBINATION THERAPY IN CHRONIC HEPATITIS C PATIENTS
|
謝明彥;戴嘉言;黃志富;林子堯;余明隆;莊萬龍 |
| 高雄醫學大學 |
2007 |
葡萄糖異常與慢性C型肝炎患者接受長效型干擾素（pegylated interferon alfa）合併ribavirin治療反應之關聯性研究
|
謝明彥;戴嘉言;李立柏;余明隆;王良彥;莊萬龍;張文宇 |
| 高雄醫學大學 |
2006 |
A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan.
|
余明隆;戴嘉言;林子堯;李立柏;侯乃仁;謝明彥;陳信成;謝明裕;王良彥;張文宇;莊萬龍 ; Ming-Lung Yu;Chia-Yen Dai;Zu-Yau Lin;Li-Po Lee;Nei-Jen Hou;Ming-Yen Hsieh;Shinn-Cherng Chen;Ming-Yuh Hsieh;Liang-Yen Wang;Wen-Yu Chang;Wan-Long Chuang |
| 高雄醫學大學 |
2006 |
Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy.
|
余明隆;戴嘉言;李立柏;謝明彥;侯乃仁;黃志富;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍 ; Yu ML;Dai CY;Lee LP;Hsieh MY;Hou NJ;Huang JF;Lin ZY;Chen SC;Hsieh MY;Wang LY;Chang WY;Chuang WL |
| 高雄醫學大學 |
2006 |
Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection.
|
戴嘉言;莊萬龍;張文宇;陳信成;李立柏;謝明彥;侯乃仁;林子堯;黃志富;謝明裕;王良彥;余明隆 ; Dai CY;Chuang WL;Chang WY;Chen SC;Lee LP;Hsieh MY;Hou NJ;Lin ZY;Huang JF;Hsieh MY;Wang LY;Yu ML |
| 高雄醫學大學 |
2006 |
SEN and hepatitis virus infections in nontransfused children and pediatric thalassemia patients with multiple transfusions in Taiwan
|
邱世欣;黃志富;張泰琮;謝明彥;戴嘉言;張文宇;莊萬龍 ; Chiou, SS;Huang, JF;Chang, TT;Hsieh, MY;Dai, CY;Yu, ML;Chang, WY;WL , Chuang |
| 高雄醫學大學 |
2006 |
A randomized study of peginterferon and ribavirin for 16 vs 24 weeks in patients with genotype 2 chronic hepatitis C
|
余明隆;戴嘉言;黃志富;侯乃仁;李立柏;謝明彥;丘長富;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍 |
| 高雄醫學大學 |
2006 |
Predictors for early mortality in lamivudine-treated patients with chronic hepatitis B-related decompensation in Taiwan ”has been accepted for poster presentation at the forthcoming.
|
戴嘉言;莊萬龍;李立柏;謝明裕;侯乃仁;陳信成;林子堯;謝明彥;王良彥;黃志富;張文宇;余明隆 |
| 高雄醫學大學 |
2006 |
A randomized, controlled, open-label study of peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for 16 vs. 24 weeks in patients with genotype 2 hepatitis C infection
|
余明隆;黃志富;侯乃仁;李立柏;謝明彥;丘長富;林子堯;陳信成;謝明彥;王良彥;張文宇;莊萬龍 |
| 高雄醫學大學 |
2006 |
Predictors for early mortality in lamivudine-treated patients with chronic hepatitis B-related decompensation in Taiwan ”has been accepted for poster presentation at the forthcoming.
|
戴嘉言;莊萬龍;李立柏;謝明裕;侯乃仁;陳信成;林子堯;謝明彥;王良彥;黃志富;張文宇;余明隆 |
| 高雄醫學大學 |
2005 |
Co-infection of SENV-D among chronic hepatitis C patients treated with combination therapy with high-dose interferon-alfa and ribavirin.
|
戴嘉言;莊萬龍;張文宇;陳信成;李立柏;謝明彥;侯乃仁;林子堯;謝明裕;王良彥;余明隆 ; Dai CY;Chuang WL;Chang WY;Chen SC;Lee LP;Hsieh MY;Hou NJ;Lin ZY;Hsieh MY;Wang LY;Yu ML |
| 高雄醫學大學 |
2005 |
Polymorphisms in the interferon-gamma gene at position+874 in patients with chronic hepatitis C treated with high-dose interferon-alpha and ribavirin
|
戴嘉言;莊萬龍;張文宇;陳信成;李立柏;謝明彥;侯乃仁;林子堯;謝明裕;王良彥;余明隆 ; Dai CY;Chuang WL;Chang WY;Chen SC;Lee LP;Hsieh MY;Hou NJ;Lin ZY;Hsieh MY;Wang LY;Yu ML |
| 高雄醫學大學 |
2005 |
慢性C型肝炎患者臨床表徵及以甲型干擾素及ribavirin合併治療療效與丙型干擾素基因多型性基因多型性相關性
|
謝明彥;戴嘉言;余明隆;李立柏;莊萬龍 |
| 高雄醫學大學 |
2005 |
Interferon-alpha could reduce the occurrence of liver cirrhosis and hepatocellular carcinoma for naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study
|
莊萬龍;余明隆;戴嘉言;陳信成;李立柏;謝明彥;林子堯;謝明裕;王良彥;蔡榮發;黃志富 |
| 高雄醫學大學 |
2005 |
A randomized trial of 24-week versus 48-week courses of peginterferon alpha-2b plus ribavirin for genotype-1b infected chronic hepatitis C patients: a pilot study in Taiwan
|
余明隆;戴嘉言;林子堯;李立柏;謝明彥;陳信成;謝明裕;王良彥;張文宇;莊萬龍 |
| 高雄醫學大學 |
2005 |
小型肝細胞癌血清第二型類胰島素生長因子之研究
|
蔡榮發;王良彥;謝明裕;陳信成;莊萬龍;林子堯;余明隆;戴嘉言;謝明彥;李立柏 |
| 高雄醫學大學 |
2005 |
甲型腫瘤壞死因子促動基因–308基因多型性與高劑量甲型干擾素合併ribavirin治療慢性C型肝炎療效之關聯
|
戴嘉言;余明隆;.莊萬龍;李立柏;謝明彥;侯乃仁;林子堯;陳信成;謝明裕;王良彥;蔡榮發;王良彥;蔡榮發;張文宇 |
| 高雄醫學大學 |
2005 |
感染基因型第二型之慢性C型肝炎病患以長效型干擾素合併Rivbavirin治療16及24週療程之比較:期中分析
|
戴嘉言;余明隆;李立柏;謝明彥;侯乃仁;黃志富;丘長富;林子堯;陳信成;謝明裕;王良彥;莊萬龍;張文宇 |
| 高雄醫學大學 |
2005 |
Polymorphisms in the Interferon-gamma gene at position +874 in patients with chronic Hepatitis C treated with high dose Interferon-Alpha and Ribavirin
|
戴嘉言;莊萬龍;張文宇;陳信成;李立柏;謝明彥;侯乃仁;林子堯;謝明裕;王良彥;余明隆 |
